logo-loader

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization for its coronavirus test

Published: 13:45 07 Apr 2020 BST

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2.

Egan says the authorization confirms the quality and performance of the Logix Smart coronavirus (COVID-19) test and helps it to reach an even wider audience.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

1 hour, 47 minutes ago